Skip to main content
. 2012 Dec 27;7:102. doi: 10.1186/1750-1172-7-102

Table 4.

Treatment-emergent adverse events* during 24 months of miglustat therapy (all-enrolled population)

Adverse event
Incidence (N = 42)
  n %
Diarrhea
31
31 (74)
Flatulence
21
21 (50)
Tremor
15
15 (36)
Headache
9
9 (21)
Paresthesia
9
9 (21)
Fatigue
8
8 (19)
Dizziness
7
7 (17)
Arthralgia
6
6 (14)
Weight decreased
6
6 (14)
Abdominal discomfort
5
5 (12)
Hypoesthesia 5 5 (12)

*Adverse events with ≥10% incidence.